Phoenix Asia Holdings Limited Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $384.5M
- Price
- $19.72
- % Change (Daily % change from the live per-ticker quote feed.)
- -18.59%
- Volume
- 40.0K
Quote data as of 5:23 AM ET
About
Phoenix Asia Holdings Limited engages in the substructure works in Hong Kong. The company undertakes site formation, ground investigation and foundation works. It also provides construction services, such as structural steelworks. The company was incorporated in 2024 and is based in Kowloon Bay, Hong Kong. Phoenix Asia Holdings Limited is a subsidiary of Phoenix Asia Holdings Limited.
Quick stats
Shares outstanding21.6M
Computed float5.5M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorIndustrials
IndustryConstruction
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002035709
Websitehttps://www.winfield.hk
AI Summary
AI-generated2mo agocriticalbullishm and aPhoenix Asia Holdings Limited Announces Entering into Stock Acquisition Agreement and Convertible Promissory Note
Phoenix Asia Holdings announced a definitive agreement to acquire 100% of ACEA Pharma, a clinical-stage pharmaceutical company, in a reverse merger transaction valued at $1 billion.
The consideration consists of 100 million newly-issued ordinary shares, and the company also issued a $20 million convertible promissory note to its controlling stockholder for advisory services.
Closing is expected in the second quarter of 2026, subject to regulatory approvals including Nasdaq review of the reverse takeover.
Red flags
- Transaction structure constitutes a reverse merger requiring Nasdaq review
- Significant dilution: issuance of 100,000,000 shares for the acquisition and potential conversion of the $20M note
- Note issued to controlling stockholder for 'advisory services' at a fixed conversion price of $10.00